Cargando…
Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting
Stem cell transplantation is a promising strategy for therapeutic cardiac regeneration, but current therapies are limited by inefficient interaction between potentially beneficial cells (either exogenously transplanted or endogenously recruited) and the injured tissue. Here we apply targeted nanomed...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Pub. Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175574/ https://www.ncbi.nlm.nih.gov/pubmed/25205020 http://dx.doi.org/10.1038/ncomms5880 |
_version_ | 1782336500629766144 |
---|---|
author | Cheng, Ke Shen, Deliang Hensley, M. Taylor Middleton, Ryan Sun, Baiming Liu, Weixin De Couto, Geoffrey Marbán, Eduardo |
author_facet | Cheng, Ke Shen, Deliang Hensley, M. Taylor Middleton, Ryan Sun, Baiming Liu, Weixin De Couto, Geoffrey Marbán, Eduardo |
author_sort | Cheng, Ke |
collection | PubMed |
description | Stem cell transplantation is a promising strategy for therapeutic cardiac regeneration, but current therapies are limited by inefficient interaction between potentially beneficial cells (either exogenously transplanted or endogenously recruited) and the injured tissue. Here we apply targeted nanomedicine to achieve in vivo cell-mediated tissue repair, imaging and localized enrichment without cellular transplantation. Iron nanoparticles are conjugated with two types of antibodies (one against antigens on therapeutic cells and the other directed at injured cells) to produce magnetic bifunctional cell engager (MagBICE). The antibodies link the therapeutic cells to the injured cells, whereas the iron core of MagBICE enables physical enrichment and imaging. We treat acute myocardial infarction by targeting exogenous bone marrow-derived stem cells (expressing CD45) or endogenous CD34-positive cells to injured cardiomyocytes (expressing myosin light chain. Targeting can be further enhanced by magnetic attraction, leading to augmented functional benefits. MagBICE represents a generalizable platform technology for regenerative medicine. |
format | Online Article Text |
id | pubmed-4175574 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Nature Pub. Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-41755742014-10-02 Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting Cheng, Ke Shen, Deliang Hensley, M. Taylor Middleton, Ryan Sun, Baiming Liu, Weixin De Couto, Geoffrey Marbán, Eduardo Nat Commun Article Stem cell transplantation is a promising strategy for therapeutic cardiac regeneration, but current therapies are limited by inefficient interaction between potentially beneficial cells (either exogenously transplanted or endogenously recruited) and the injured tissue. Here we apply targeted nanomedicine to achieve in vivo cell-mediated tissue repair, imaging and localized enrichment without cellular transplantation. Iron nanoparticles are conjugated with two types of antibodies (one against antigens on therapeutic cells and the other directed at injured cells) to produce magnetic bifunctional cell engager (MagBICE). The antibodies link the therapeutic cells to the injured cells, whereas the iron core of MagBICE enables physical enrichment and imaging. We treat acute myocardial infarction by targeting exogenous bone marrow-derived stem cells (expressing CD45) or endogenous CD34-positive cells to injured cardiomyocytes (expressing myosin light chain. Targeting can be further enhanced by magnetic attraction, leading to augmented functional benefits. MagBICE represents a generalizable platform technology for regenerative medicine. Nature Pub. Group 2014-09-10 /pmc/articles/PMC4175574/ /pubmed/25205020 http://dx.doi.org/10.1038/ncomms5880 Text en Copyright © 2014, Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Article Cheng, Ke Shen, Deliang Hensley, M. Taylor Middleton, Ryan Sun, Baiming Liu, Weixin De Couto, Geoffrey Marbán, Eduardo Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting |
title | Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting |
title_full | Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting |
title_fullStr | Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting |
title_full_unstemmed | Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting |
title_short | Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting |
title_sort | magnetic antibody-linked nanomatchmakers for therapeutic cell targeting |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175574/ https://www.ncbi.nlm.nih.gov/pubmed/25205020 http://dx.doi.org/10.1038/ncomms5880 |
work_keys_str_mv | AT chengke magneticantibodylinkednanomatchmakersfortherapeuticcelltargeting AT shendeliang magneticantibodylinkednanomatchmakersfortherapeuticcelltargeting AT hensleymtaylor magneticantibodylinkednanomatchmakersfortherapeuticcelltargeting AT middletonryan magneticantibodylinkednanomatchmakersfortherapeuticcelltargeting AT sunbaiming magneticantibodylinkednanomatchmakersfortherapeuticcelltargeting AT liuweixin magneticantibodylinkednanomatchmakersfortherapeuticcelltargeting AT decoutogeoffrey magneticantibodylinkednanomatchmakersfortherapeuticcelltargeting AT marbaneduardo magneticantibodylinkednanomatchmakersfortherapeuticcelltargeting |